足潰瘍に対するデクスメデトミジン鎮静下の末梢神経ブロックによる手術についての論文

Nakamura H, Makiguchi T, Yamada Y, Sakurai K, Tsunoda A, Tomaru N, Shirabe K, Yokoo S

Surgery With Peripheral Nerve Block Under Dexmedetomidine Sedation for Foot Ulcer

PRS-GLOB OPEN. 2024 NOV;12(11)

PMID: 39583786 DOI: 10.1097/GOX.0000000000006333 WoS: WOS:001373647000003

Ishibashi Y, Nojiri Y, Takahashi Y, Takahashi S, Fukuda N, Hiroi S

Oxf Med Case Rep. 2024 NOV 20;2024(11)

PMID: 39575091 DOI: 10.1093/omcr/omae130 WoS: WOS:001360362800001

大腸憩室出血の管理における早期大腸内視鏡検査前の緊急造影CT検査：多施設ランダム化比較試験についての論文

Hirai Y, Uraoka T, Wada M, Mori H, Fujimoto A, Sakakibara Y, Toyokawa T, Kagaya T, Sasaki Y, Mannami T, Kuwai T, Watanabe N, Hamada H, Esaka N, Kimura T, Fujii H, Hosoda Y, Shimada M, Miyabayashi H, Somada S, Mabe K, Inoue S, Saito H, Furuya K, Kawamura N, Kudo T, Hori K, Sakamoto N, Kato M, Higuchi N, Harada N, NHO Network Gastrointestinal Study Grp

Urgent Contrast-Enhanced Computed Tomography before Early Colonoscopy in the Management of Colonic Diverticular Bleeding: A Multicenter Randomized Controlled Trial

Digestion. 2024 OCT 15;

PMID: 39406199 DOI: 10.1159/000541942 WoS: WOS:001354598700001

免疫療法時代の臨床における切除不能肝細胞癌に対するデュルバルマブ＋トレメリムマブ治療の有効性についての論文

Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ohama H, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Kawata K, Naganuma A, Kosaka H, Matono T, Kuroda H, Yata Y, Nishikawa H, Imai M, Aoki T, Ochi H, Tada F, Nakamura S, Nakamura Y, Nouso K, Morishita A, Itokawa N, Okubo T, Arai T, Tsutsui A, Nagano T, Tanaka K, Tanaka H, Koshiyama Y, Kanayama Y, Noritake H, Enomoto H, Kaibori M, Hiasa Y, Kudo M, Kumada T, RELPEC Grp, HCC 48 Grp

Efficacy of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma in immunotherapy era clinical practice

Hepatol Res. 2024 NOV 11;

PMID: 39526824 DOI: 10.1111/hepr.14136 WoS: WOS:001354865600001

切除不能進行・再発胃癌患者における化学療法およびニボルマブ第一選択治療に対する治療感受性のバイオマーカーとしての予後栄養指標：多施設共同研究についての論文

Nakazawa N, Sano A, Kumakura Y, Yamashita T, Tanaka N, Saito K, Kimura A, Kasuga K, Nakazato K, Yoshinari D, Shimizu H, Ubukata Y, Hosaka H, Shiraishi T, Sakai M, Sohda M, Shirabe K, Saeki H

Prognostic Nutrition Index as a Biomarker for Treatment Sensitivity to Chemotherapy and Nivolumab as the First-Line Treatment in Patients with Unresectable Advanced or Recurrent Gastric Cancer: A Multicenter Study

Oncology. 2024 OCT 24;

PMID: 39447553 DOI: 10.1159/000541544 WoS: WOS:001354587500001

乳癌におけるFAM83Gの臨床的意義：トリプルネガティブサブタイプおよび予後との関連性についての論文

Ikeda T, Honda CK, Kurozumi S, Yokobori T, Katayama A, Masuda K, Oyama T, Kaira K, Horiguchi J, Shirabe K, Fujii T

Clinical Significance of FAM83G in Breast Cancer: Association With Triple-negative Subtype and Prognosis

Anticancer Res. 2024 NOV;44(11):4877-4883.

PMID: 39477305 DOI: 10.21873/anticanres.17313 WoS: WOS:001351595700020

肝細胞癌患者におけるアルブミングレードの予後効果についての論文

Hirano Y, Nouso K, Kariyama K, Hiraoka A, Shiota S, Wakuta A, Yasuda S, Toyoda H, Tsuji K, Hatanaka T, Kakizaki S, Naganuma A, Tada T, Itobayashi E, Ishikawa T, Shimada N, Takaguchi K, Tsutsui A, Nagano T, Imai M, Nakamura S, Kumada T, Real-Life Practice Experts HCC RELPEC Study Grp Japan

Prognostic Efficacy of the Albumin Grade in Patients with Hepatocellular Carcinoma

Acta Med Okayama. 2024 OCT;78(5):377-386.

PMID: 39467656 WoS: WOS:001343346400004

微小血管の状態とストレス動的CT灌流画像の診断能との関係についての論文

Nagasawa N, Nakamura S, Ota H, Ogawa R, Nakashima H, Hatori N, Wang YN, Kurita T, Dohi K, Sakuma H, Kitagawa K

Relationship between microvascular status and diagnostic performance of stress dynamic CT perfusion imaging

Eur Radiol. 2024 OCT 17;

PMID: 39419862 DOI: 10.1007/s00330-024-11136-1 WoS: WOS:001338546100001

切除不能進行・再発胃癌患者における化学療法＋ニボルマブ併用療法のファーストラインとしての治療効果を評価するためのバイオマーカーの同定：多施設共同研究についての論文

Nakazawa N, Sohda M, Hosoi N, Watanabe T, Kumakura Y, Yamashita T, Tanaka N, Saito K, Kimura A, Kasuga K, Nakazato K, Yoshinari D, Shimizu H, Ubukata Y, Hosaka H, Sano A, Sakai M, Ogawa H, Shirabe K, Saeki H

Identification of Biomarkers for Assessing Treatment Efficacy of Chemotherapy plus Nivolumab as the First Line in Patients with Unresectable Advanced or Recurrent Gastric Cancer: A Multicenter Study

Oncology. 2024 SEP 12;

PMID: 39447553 DOI: 10.1159/000540841 WoS: WOS:001329232200001

ASOビジュアルアブストラクト：切除不能進行・再発胃癌に対する第一選択治療としての化学療法＋ニボルマブ投与後の転換手術とGustave Roussy免疫スコアを用いたバイオマーカー研究-多施設共同研究についての論文

Nakazawa N, Sohda M, Hosoi N, Watanabe T, Kumakura Y, Yamashita T, Tanaka N, Saito K, Kimura A, Kasuga K, Nakazato K, Yoshinari D, Shimizu H, Ubukata Y, Hosaka H, Sano A, Sakai M, Ogawa H, Shirabe K, Saeki H

ASO Visual Abstract: Conversion Surgery After Chemotherapy Plus Nivolumab as the First-Line Treatment for Unresectable Advanced or Recurrent Gastric Cancer and a Biomarker Study Using the Gustave Roussy Immune Score-A Multicenter Study

Ann Surg Oncol. 2024 OCT 4;

PMID: 39365547 DOI: 10.1245/s10434-024-16313-6 WoS: WOS:001328939600003

術後患者におけるサージカルマスク同時使用による酸素投与の最適方法の検討：無作為クロスオーバー試験についての論文

Kamiyama A, Takazawa T, Matsui Y, Nagumo K, Arai S, Saito S

Investigation of the optimal method of oxygen administration with simultaneous use of a surgical mask in postoperative patients: a randomized cross-over study

JA CLIN REP. 2024 SEP 28;10(1)

PMID: 39340699 DOI: 10.1186/s40981-024-00741-0 WoS: WOS:001325041400001

α-フェトプロテインとdes-γ-カルボキシプロトロンビンはデュルバルマブ＋トレメリムマブ療法を受けた肝細胞癌患者の客観的奏効を予測できることについての論文

Saeki I, Shimose S, Tomonari T, Ito T, Tani J, Takeuchi Y, Yoshioka N, Naito T, Takeuchi M, Kakizaki S, Hatanaka T, Sasaki K, Yasunaka T, Sakata M, Iwamoto H, Itano S, Shirono T, Tanabe N, Yamamoto T, Kanayama Y, Naganuma A, Nishina S, Otsuka M, Kobara H, Kawashima H, Takayama T, Kawaguchi T, Yamasaki T, Takami T, Hepatol Investigator Expertsin Japan HIVE J Study Grp

Alpha-fetoprotein and des-gamma-carboxy prothrombin can predict the objective response of patients with hepatocellular carcinoma receiving durvalumab plus tremelimumab therapy

PLoS One. 2024 SEP 25;19(9)

PMID: 39321197 DOI: 10.1371/journal.pone.0311084 WoS: WOS:001320142100036

Hatori K, Mohara J, Shibata S, Murata M, Fukuda N, Hiroi S, Koyano T

Cardiac calcified amorphous tumor in a patient with lung cancer

Gen Thorac Cardiovasc Surg Cases. 2024 AUG 13;3(1)

PMID: 39517008 DOI: 10.1186/s44215-024-00161-7 WoS: WOS:001316568300001

成人大動脈瘤患者における鎖骨下動脈-下行大動脈バイパス術後の偽動脈瘤の外科的管理についての論文

Hatori K, Mohara J, Murata M, Koyano T

Surgical management of pseudoaneurysm after subclavian artery-to-descending aorta bypass in an adult patient with aortic coarctation

Gen Thorac Cardiovasc Surg Cases. 2024 MAY 2;3(1)

PMID: 39517019 DOI: 10.1186/s44215-024-00154-6 WoS: WOS:001316568100001

肝細胞癌に対するアテゾリズマブおよびベバシズマブ治療の臨床転帰と脾臓容積増加に影響する因子および脾臓容積変動との関連：レトロスペクティブ解析についての論文

Hatanaka T, Saito N, Kakizaki S, Hiraoka A, Tada T, Kariyama K, Tani J, Takaguchi K, Itobayashi E, Ishikawa T, Toyoda H, Kawata K, Naganuma A, Yata Y, Ohama H, Matono T, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Nakamura S, Kumada T, Real Life Practice Experts HCC RELPEC Study Grp

Factors Affecting an Increase in Spleen Volume and Association of Spleen Volume Variation with the Clinical Outcomes of Atezolizumab and Bevacizumab Treatment for Hepatocellular Carcinoma: A Retrospective Analysis

Oncology. 2024 AUG 20;

PMID: 39163847 DOI: 10.1159/000541002 WoS: WOS:001316023500001

デジタルブレストトモシンセシスの画質向上のためのアテンションゲートを組み合わせたサイクル整合型生成アドバーサリアルネットワークによる再構成前処理についての論文

Gomi T, Ishihara K, Yamada S, Koibuchi Y

Pre-Reconstruction Processing with the Cycle-Consist Generative Adversarial Network Combined with Attention Gate to Improve Image Quality in Digital Breast Tomosynthesis

Diagnostics. 2024 SEP;14(17)

PMID: 39272741 DOI: 10.3390/diagnostics14171957 WoS: WOS:001310986600001

アテゾリズマブとベバシズマブを投与された切除不能肝細胞癌患者に対する転換療法の予測因子と生存転帰：転換療法、部分奏効例、完全奏効例の比較解析についての論文

Hatanaka T, Kakizaki S, Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Toyoda H, Ogawa C, Nishikawa H, Nishimura T, Kawata K, Kosaka H, Naganuma A, Yata Y, Ohama H, Kuroda H, Matono T, Aoki T, Kanayama Y, Tanaka K, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Nakamura S, Enomoto H, Kaibori M, Hiasa Y, Kudo M, Kumada T

Predictive factors and survival outcome of conversion therapy for unresectable hepatocellular carcinoma patients receiving atezolizumab and bevacizumab: Comparative analysis of conversion, partial response and complete response patients

Aliment Pharmacol Ther. 2024 NOV;60(10):1361-1373.

PMID: 39233317 DOI: 10.1111/apt.18237 WoS: WOS:001305987700001

切除不能進行・再発胃癌に対する化学療法＋ニボルマブ第一選択療法後の転換手術とGustave Roussy免疫スコアを用いたバイオマーカー研究：多施設共同研究についての論文

Nakazawa N, Sohda M, Hosoi N, Watanabe T, Kumakura Y, Yamashita T, Tanaka N, Saito K, Kimura A, Kasuga K, Nakazato K, Yoshinari D, Shimizu H, Ubukata Y, Hosaka H, Sano A, Sakai M, Ogawa H, Shirabe K, Saeki H

Conversion Surgery After Chemotherapy Plus Nivolumab as the First-Line Treatment for Unresectable Advanced or Recurrent Gastric Cancer and a Biomarker Study Using the Gustave Roussy Immune Score: A Multicenter Study

Ann Surg Oncol. 2024 DEC;31(13):9023-9029.

PMID: 39225857 DOI: 10.1245/s10434-024-16161-4 WoS: WOS:001304668000001

持続的局所抗生物質注入による下肢壊死性筋膜炎の治療についての論文

Tomaru N, Nakamura H, Makiguchi T, Yamada Y, Yokoo S

Necrotizing Fasciitis of the Lower Extremity Treated With Continuous Local Antibiotic Perfusion

Cureus J Med Sci. 2024 AUG 14;16(8)

PMID: 39280401 DOI: 10.7759/cureus.66865 WoS: WOS:001295047800009

細胞毒性化学療法を受けている特発性間質性肺炎および進行肺癌患者の予後不良を予測する急性増悪についての論文

Miyamoto A, Michimae H, Nakahara Y, Akagawa S, Nakagawa K, Minegishi Y, Ogura T, Hontsu S, Date H, Takahashi K, Homma S, Kishi K, Nakahara Y, Ohta K, Gemma A, Nishizaka Y, Ogura T, Kimura H, Nishi K, Nakamura M, Yokomura K, Taniguchi H, Tomii K, Shindo J, Sato K, Taguchi Y, Takahashi H, Takizawa H, Homma S, Nakamura S, Yoshimura K, Usui K, Ichikado K, Bessyo A, Sugiyama H, Hasegawa Y, Nakamura H, Sagara H, Ube K, Nomura F, Kiura K, Yoshiike F, Takahashi K, Kita T, Sakai H, Bando M, Matsumoto T, Inoue T, Kijima T, Mukae H, Masuda N, Matsumoto N, Sakamaki F, Kamimura M, Takise A, Kishaba T, Nishioka Y, Kashiwabara K, Yamamoto A, Fujiuchi S, Shingyoji M, Hanaoka M, Tominaga S, Kadota J, Kasahara T, Motegi M, Harada T, Ishikawa S, Suda T, Tomizawa Y, Hayashi R, Shinoda M, Terada M, Jin Y, Shikama Y, Kikuchi T, Kido K, Yokoyama A, Fuke S, Nagase H, Tanaka H, Hizawa N, Miyazaki K, Ikushima S, Sakai N, Hoshino T, Mishima M, Ohnishi H, Imai H, Nagashima S, Kojima E, Ohishi S, Ohe Y, Iwakami S, Mineshita M, Komase Y, Harada H, Imokawa S, Watanabe H, Ichiki M, Kuwano K, Takahashi N, Chonabayashi N, Hisada T, Yoshida M, Hirata K, Watanabe K, Sugino Y, Yoshioka S, Tomioka H, Aoshima M, Sugimoto Y, Ichinose M, Tamaki S, Tsuchiya M, Katayama H, Okochi Y, Tanaka H, Ogata K, Tsuburai T, Honda I, Investigators Grp Lung Canc IIP

Acute exacerbation predicting poor outcomes in idiopathic interstitial pneumonia and advanced lung cancer patients undergoing cytotoxic chemotherapy

Sci Rep. 2024 MAY 3;14(1)

PMID: 38702426 DOI: 10.1038/s41598-024-60833-w WoS: WOS:001253660400001

インターロイキン7遺伝子変異と免疫チェックポイント阻害剤の毒性および有効性との関連を評価：ヨーロッパのゲノムワイド関連研究の結果に基づく日本人集団の再現研究についての論文

Miyamoto H, Kondo Y, Itobayashi E, Uehara M, Hiraoka A, Kudo M, Kakizaki S, Kagawa T, Miuma S, Suzuki T, Sugi K, Suyama K, Beppu T, Toyoda H, Yoshiji H, Uojima H, Miyase S, Inoue K, Tamori A, Ito T, Shimose S, Suda G, Hayashi T, Onishi M, Narahara S, Watanabe T, Iwatsuki M, Fukushima S, Tanaka Y

Evaluation of the associations of interlukin-7 genetic variants with toxicity and efficacy of immune checkpoint inhibitors: A replication study of a Japanese population, based on the findings of a European genome-wide association study

Hepatol Res. 2024 DEC;54(12):1215-1225.

PMID: 38990762 DOI: 10.1111/hepr.14092 WoS: WOS:001268554300001

切除不能肝細胞癌患者に対するデュルバルマブ＋トレメリムマブの実臨床における初期臨床経験についての論文

Shimose S, Saeki I, Tomonari T, Ito T, Tani J, Takeuchi Y, Yoshioka N, Naito T, Takeuchi M, Kakizaki S, Hatanaka T, Sasaki K, Yasunaka T, Sakata M, Iwamoto H, Itano S, Shirono T, Tanabe N, Yamamoto T, Naganuma A, Nishina S, Otsuka M, Kawashima H, Takayama T, Takami T, Kawaguchi T

Initial clinical experience with durvalumab plus tremelimumab in patients with unresectable hepatocellular carcinoma in real-world practice

Oncol Lett. 2024 AUG;28(2)

PMID: 38979550 DOI: 10.3892/ol.2024.14530 WoS: WOS:001268118500001

実臨床においてアテゾリズマブとベバシズマブの併用療法を受けた肝細胞癌患者の転帰で、第3相IMbrave150試験の組み入れ基準を満たした、または満たさなかった症例についての論文

Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Nishikawa H, Tsuji K, Ishikawa T, Tajiri K, Koshiyama Y, Toyoda H, Ogawa C, Hatanaka T, Kakizaki S, Kawata K, Ohama H, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Nishimura T, Imai M, Kosaka H, Naganuma A, Matono T, Aoki T, Kuroda H, Yata Y, Koizumi Y, Nakamura S, Enomoto H, Kaibori M, Hiasa Y, Kudo M, Real Life Practice Experts HCC, Hepatocellular Carcinoma Experts

Outcomes of patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab in real-world clinical practice who met or did not meet the inclusion criteria for the phase 3 IMbrave150 trial

Aliment Pharmacol Ther. 2024 JUL;60(2):233-245.

PMID: 38716823 DOI: 10.1111/apt.18037 WoS: WOS:001215665600001

アテゾリズマブとベバシズマブの併用療法を受けた進行肝細胞癌患者における活性予測因子としての有害事象についての論文

Persano M, Rimini M, Tada T, Suda G, Shimose S, Kudo M, Rossari F, Yoo C, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Bergamo F, Amadeo E, Vitiello F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Iavarone MA, Cabibbo G, Montes M, Foschi FG, Vivaldi C, Soldà C, Sho T, Niizeki T, Nishida N, Steup C, Bruccoleri M, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Hiraoka A, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Foti S, Camera S, Piscaglia F, Scartozzi M, Cascinu S, Casadei-Gardini A

Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab

Target Oncol. 2024 JUL;19(4):645-659.

PMID: 38689194 DOI: 10.1007/s11523-024-01061-0 WoS: WOS:001211449700001

グラスゴー予後スコアと体格指数は、抗線維化薬ピルフェニドンとニンテダニブの短期投与中止を予測することについての論文

Takehara K, Koga Y, Hachisu Y, Utsugi M, Sawada Y, Saito Y, Yoshimi S, Yatomi M, Tsurumaki H, Shin Y, Wakamatsu I, Kasahara N, Yamaguchi K, Umetsu K, Kouno S, Nakagawa J, Sunaga N, Maeno T, Hisada T

Glasgow prognostic score and body mass index predict short-term discontinuation of the antifibrotic agents pirfenidone and nintedanib

Respir Investig. 2024 MAY;62(3):388-394.

PMID: 38460356 DOI: 10.1016/j.resinv.2024.02.012 WoS: WOS:001203246200001

トリプルネガティブ乳癌における予後因子としてのヒト上皮成長因子2の不均一性の有用性についての論文

Narusawa E, Kurozumi S, Katayama A, Koibuchi Y, Ogawa A, Takata D, Tokuda S, Obayashi S, Oyama T, Horiguchi J, Shirabe K, Fujii T

Utility of human epidermal growth factor 2 heterogeneity as a prognostic factor in triple-negative breast cancer

Med Mol Morphol. 2024 SEP;57(3):177-184.

PMID: 38619618 DOI: 10.1007/s00795-024-00386-z WoS: WOS:001204309400001

アテゾリズマブとベバシズマブの併用療法を受けた肝細胞癌患者の転帰に及ぼす疾患病因の影響：リアルワールドの多施設共同研究についての論文

Rossari F, Tada T, Suda G, Shimose S, Kudo M, Yoo C, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Bergamo F, Amadeo E, Vitiello F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Iavarone M, Cabibbo G, Montes M, Foschi FG, Vivaldi C, Solda C, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Hiraoka A, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Persano M, Foti S, Camera S, Stefanini B, Scartozzi M, Cascinu S, Casadei-Gardini A, Rimini M

Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a real-world, multicenter study

Liver Cancer. 2024 OCT;13(5):522-536.

PMID: 39296620 DOI: 10.1159/000537915 WoS: WOS:001202939200001

日本人C型肝炎ウイルス肝細胞癌患者における直接作用型抗ウイルス薬開発後の臨床転帰の変化についての論文

Ohama H, Hiraoka A, Tada T, Kariyama K, Itobayashi E, Tsuji K, Ishikawa T, Toyoda H, Hatanaka T, Kakizaki S, Naganuma A, Tada F, Tanaka H, Nakamura S, Nouso K, Tanaka K, Kumada T, Real Life Practice Experts HCC, HCC 48 Grp

Changes in clinical outcomes in Japanese patients with hepatocellular carcinoma due to hepatitis C virus following the development of direct-acting antiviral agents

J Gastroenterol Hepatol. 2024 JUL;39(7):1394-1402.

PMID: 38602340 DOI: 10.1111/jgh.16553 WoS: WOS:001200040400001

肝細胞癌に対するアテゾリズマブとベバシズマブの併用療法で新たに開発された予後予測スコアの臨床的有用性についての論文

Ohama H, Hiraoka A, Tada T, Hirooka M, Kariyama K, Hatanaka T, Tani J, Takaguchi K, Atsukawa M, Itobayashi E, Nishimura T, Tsuji K, Tajiri K, Ishikawa T, Yasuda S, Toyoda H, Fukunishi S, Ogawa C, Kakizaki S, Shimada N, Naganuma A, Kawata K, Kosaka H, Kuroda H, Matono T, Yata Y, Ochi H, Tada F, Nouso K, Morishita A, Itokawa N, Okubo T, Arai T, Tsutsui A, Nagano T, Yokohama K, Nishikawa H, Imai M, Koizumi Y, Nakamura S, Iijima H, Kaibori M, Hiasa Y, Kumada T, Representing Real Life Practice

Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinoma

Cancer Rep-US. 2024 APR;7(4)

PMID: 38577725 DOI: 10.1002/cnr2.2042 WoS: WOS:001197105300001

ステージII/IIIの大腸癌におけるUFT/LV Versus UFT/LVプラスPSKによる補助化学療法についての論文

Ogawa H, Shiraishi T, Okada T, Miyamae Y, Motegi Y, Shirabe K, Saeki H

Adjuvant Chemotherapy With UFT/LV Versus UFT/LV Plus PSK in Stage II/III Colorectal Cancer

Anticancer Res. 2024 FEB;44(2):805-814.

PMID: 38307591 DOI: 10.21873/anticanres.16872 WoS: WOS:001160678100014

レンバチニブまたはアテゾリズマブとベバシズマブの一次治療を受けた切除不能肝細胞癌患者の予後に対する肥満度の影響についての論文

Rimini M, Stefanini B, Tada T, Suda G, Shimose S, Kudo M, Finkelmeier F, Yoo C, Presa J, Amadeo E, Genovesi V, De Grandis MC, Iavarone M, Marra F, Foschi F, Tamburini E, Rossari F, Vitiello F, Bartalini L, Soldà C, Tovoli F, Vivaldi C, Lonardi S, Silletta M, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Himmelsbach V, Montes M, Hiraoka A, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Persano M, Camera S, Foti S, Aldrighetti L, Cascinu S, Casadei-Gardini A, Piscaglia F

Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab

Liver Int. 2024 MAY;44(5):1108-1125.

PMID: 38517286 DOI: 10.1111/liv.15885 WoS: WOS:001190932900001

症候性肝嚢胞に対する硬化療法を併用した経皮的ドレナージと非併用の治療効果についての論文

Takakusagi S, Kakizaki S, Saito N, Kohga T, Ueno T, Hatanaka T, Namikawa M, Tojima H, Naganuma A, Kosone T, Uraoka T, Takagi H

The Treatment Effects of Percutaneous Drainage with or without Sclerotherapy for Symptomatic Liver Cysts

Gastrointest Disord. 2024 MAR;6(1):13-25.

DOI: 10.3390/gidisord6010002 WoS: WOS:001192060000001

糖尿病患者における大胸筋筋膜炎：症例報告と文献レビューについての論文

Tsunoda A, Nakamura H, Makiguchi T, Tomaru N, Yokoo S

Pectoralis Major Pyomyositis in a Patient With Diabetes: A Case Report and Literature Review

Cureus J Med Sci. 2024 FEB 6;16(2)

PMID: 38455799 DOI: 10.7759/cureus.53689 WoS: WOS:001168632600023

切除不能肝細胞癌の超高齢患者におけるレンバチニブの安全性と有効性についての論文

Camera S, Rimini M, Rossari F, Tada T, Suda G, Shimose S, Kudo M, Yoo C, Cheon J, Finkelmeier F, Lim HY, Presa J, Masi G, Bergamo F, Salani F, Marseglia M, Amadeo E, Vitiello F, Kumada T, Sakamoto N, Iwamoto H, Aoki T, Chon HJ, Himmelsbach V, Iavarone M, Cabibbo G, Montes M, Foschi FG, Vivaldi C, Lonardi S, Sho T, Niizeki T, Nishida N, Steup C, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Shimada N, Kawata K, Hiraoka A, Tada F, Ohama H, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Imai M, Kosaka H, Naganuma A, Koizumi Y, Nakamura S, Kaibori M, Iijima H, Hiasa Y, Persano M, Foti S, Piscaglia F, Scartozzi M, Cascinu S, Casadei-Gardini A

Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma

Target Oncol. 2024 JAN 22;

PMID: 38252195 DOI: 10.1007/s11523-023-01029-6 WoS: WOS:001156908500001

代謝機能障害に伴う脂肪性肝疾患を有するアジア人患者における有意な線維化の予測を機械学習が改善 - アジアにおける腸と肥満（GO-ASIA）研究についての論文

Verma N, Duseja A, Mehta M, De A, Lin HP, Wong VWS, Wong GLH, Rajaram RB, Chan WK, Mahadeva S, Zheng MH, Liu WY, Treeprasertsuk S, Prasoppokakorn T, Kakizaki S, Seki Y, Kasama K, Charatcharoenwitthaya P, Sathirawich P, Kulkarni A, Purnomo HD, Kamani L, Lee YY, Wong MS, Tan EXX, Young DY

Machine learning improves the prediction of significant fibrosis in Asian patients with metabolic dysfunction-associated steatotic liver disease - The Gut and Obesity in Asia (GO-ASIA) Study

Aliment Pharmacol Ther. 2024 MAR;59(6):774-788.

PMID: 38303507 DOI: 10.1111/apt.17891 WoS: WOS:001155768000001